Agilent Invests in Lasergen to Develop Routine NGS for Routine Clinical Use
Agilent Technologies Inc. and Lasergen, Inc. have announced that Agilent is investing $80 million in Lasergen, an emerging biotechnology company with innovative next-generation sequencing technology.
With this investment, Agilent will acquire a 48-percent ownership stake in privately held Lasergen and will join the board. Agilent has the option to acquire the remaining shares of Lasergen until March 2, 2018, for an additional consideration of $105 million.
The two companies will collaborate on building a next-generation sequencing solutions workflow for clinical applications, based on Lasergen's Lightning Terminators(tm) sequencing chemistry. Lightning Terminators offer potentially faster, more accurate and less expensive genome sequencing than other technologies currently on the market.
"Agilent is investing in a team and technology that hold great promise for the future of genetic sequencing," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group. "Agilent has been clear about its strategic intent to grow in the diagnostics space and, to that end, build a complete routine clinical NGS workflow. Our investment and collaboration are designed to accelerate Lasergen's work in commercializing their novel technology, focused on developing a sequencing workflow aimed at clinical applications."
"We're excited to collaborate with a known leader in diagnostics and genomics," said Mimi Healy, Ph.D., president and CEO of Lasergen. "Agilent's experience of providing leading products, combined with our expertise in NGS chemistry, will allow us to develop a comprehensive solution designed to meet the needs of the routine clinical NGS market."
Tags: Next Generation Sequencing
Date Published: March 8, 2016
Source article link: Agilent Technologies